Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study

ConditionIntrahepatic Cholangiocarcinoma (Icc)

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-80

SponsorShanghai Zhongshan Hospital

About this trial

Second-line regimen with or without consolidative radiotherapy in patients with oligometastatic/locally advanced unresectable intrahepatic cholangiocarcinoma: an open-label, randomised, controlled study.

Eligibility criteria

Qualifiers

(1) Advanced or metastatic intrahepatic cholangiocarcinoma confirmed by histopathology that cannot be surgically removed.

Disqualifiers

(1) Histology includes components of mixed hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or biliary adenocarcinoma.

Trial design

Treatments tested in this trial

radiotherapy
FOLFIRI or FOLFOX or Regorafenib

Treatment groups

76 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Shanghai Zhongshan Hospital

Lead sponsor

Source ClinicalTrials.gov